日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

循环肿瘤细胞可预测接受达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗的多发性骨髓瘤患者的预后

Bertamini, Luca; Fokkema, Cathelijne; Rodriguez-Otero, Paula; van Duin, Mark; Terpos, Evangelos; D'Agostino, Mattia; van der Velden, Vincent H J; van de Donk, Niels W C J; Delforge, Michel; Driessen, Christoph; Hajek, Roman; Einsele, Hermann; Vangsted, Annette; Vieyra, Diego; Attar, Ricardo; Sitthi-Amorn, Anna; Carson, Robin; Schjesvold, Fredrik; Robak, Pawel; Beksac, Meral; Spencer, Andrew; Broijl, Annemiek; Cupedo, Tom; Moreau, Philippe; Boccadoro, Mario; Sonneveld, Pieter

Vasopressor Requirements after Initiation of Venovenous Extracorporeal Membrane Oxygenation in Patients with Severe Respiratory Failure

严重呼吸衰竭患者启动静脉-静脉体外膜肺氧合(VV-ECMO)后血管加压药的需求

Nagler, Bernhard; Buchtele, Nina; Schellongowski, Peter; Robak, Oliver; Hermann, Alexander; Staudinger, Thomas

Micronucleus quantification from whole-slide haematology images using AI serves as a translatable pharmacodynamic biomarker for DNA damage response inhibitors.

利用人工智能技术从全玻片血液学图像中定量微核,可作为DNA损伤反应抑制剂的可转化药效学生物标志物。

Yong Killian H R, Robak Weronika S, Mulderrig Lee, Hughes Adina, Bystry Richard, Wantenaar Tanya, Jones Gemma N, Udriste Maria, Robertson Jack, Forment Josep V, O'Connor Lenka Oplustil, Hill Ross J

piRAT: piRNA Annotation Tool for annotating, analyzing, and visualizing piRNAs

piRAT:piRNA注释工具,用于注释、分析和可视化piRNA

Robak, Dominik; Ylla, Guillem

Evaluation of mTOR, NFκB, and BCL-2 Inhibitor Activity In Vitro on Diffuse Large B-Cell Lymphoma Cells

体外评价 mTOR、NFκB 和 BCL-2 抑制剂对弥漫性大 B 细胞淋巴瘤细胞的活性

Majchrzak, Agata; Mańka, Sylwia; Cebula-Obrzut, Barbara; Mędra, Aleksandra; Robak, Paweł; Mikulski, Damian; Witkowska, Magdalena

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

在初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中,Zanubrutinib 与 Bendamustine 和 Rituximab 的疗效比较:SEQUOIA 研究的中位 5 年随访结果

Shadman, Mazyar; Munir, Talha; Robak, Tadeusz; Brown, Jennifer R; Kahl, Brad S; Ghia, Paolo; Giannopoulos, Krzysztof; Šimkovič, Martin; Österborg, Anders; Laurenti, Luca; Walker, Patricia A; Opat, Stephen S; Ciepluch, Hanna; Greil, Richard; Hanna, Merit; Tani, Monica; Trněný, Marek; Brander, Danielle; Flinn, Ian W; Grosicki, Sebastian; Verner, Emma; Tedeschi, Alessandra; de Guibert, Sophie; Tumyan, Gayane; Laribi, Kamel; García-Marco, José A; Li, Jian-Yong; Tian, Tian; Liu, Yu; Korolkiewicz, Roman; Szeto, Andy; Tam, Constantine S; Jurczak, Wojciech

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

RESONATE-2 研究的最终分析:对慢性淋巴细胞白血病/小淋巴细胞淋巴瘤一线伊布替尼治疗进行长达 10 年的随访。

Burger, Jan A; Barr, Paul M; Robak, Tadeusz; Owen, Carolyn; Tedeschi, Alessandra; Sarma, Anita; Patten, Piers E M; Grosicki, Sebastian; McCarthy, Helen; Offner, Fritz; Szafer-Glusman, Edith; Zhou, Cathy; Szoke, Anita; Neumayr, Lynne; Dean, James P; Ghia, Paolo; Kipps, Thomas J

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

MURANO 研究:VenR 治疗复发/难治性 CLL 患者的最终分析和再治疗/交叉亚组研究结果

Kater, Arnon P; Harrup, Rosemary; Kipps, Thomas J; Eichhorst, Barbara; Owen, Carolyn J; Assouline, Sarit; Lamanna, Nicole; Robak, Tadeusz; de la Serna, Javier; Jaeger, Ulrich; Cartron, Guillaume; Montillo, Marco; Mellink, Clemens; Langerak, Anton W; Chyla, Brenda; Popovic, Relja; Jiang, Yanwen; Millen, Rosemary; Lefebure, Marcus; Thadani-Mulero, Maria; Boyer, Michelle; Seymour, John F

Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial

阿卡替尼联合苯达莫司汀和利妥昔单抗治疗初治或复发/难治性套细胞淋巴瘤患者的安全性和有效性:Ib期试验

Phillips, Tycel; Wang, Michael; Robak, Tadeusz; Gallinson, David; Stevens, Don; Patel, Krish; Ramadan, Safaa; Wun, Chuan-Chuan; Jurczak, Wojciech; Smith, Stephen D

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials

在 DREAMM-7 和 DREAMM-8 试验中调整 belantamab mafodotin 的剂量以平衡疗效和耐受性

Mateos, María-Victoria; Trudel, Suzanne; Quach, Hang; Robak, Paweł; Beksac, Meral; Pour, Ludek; Hus, Marek; Kim, Kihyun; Zherebtsova, Vera; Delimpasi, Sosana; Jelínek, Tomas; Ward, Christopher; Ho, P Joy; Vorobyev, Vladimir; Pitombeira de Lacerda, Marcelo; Aparecida-Martinez, Gracia; Spicka, Ivan; Radocha, Jakub; Cavo, Michele; Cerchione, Claudio; Fu, Chengcheng; Suzuki, Kazuhito; Rogers, Rachel; Phillips-Jones, Amy; Wang, Zhaohui; Baig, Hena; Wilkes, Jodie; Zhou, Xiaoou L; Lewis, Eric; Eccersley, Lydia; Sule, Neal; Paka, Prani; Opalinska, Joanna B; Mukhopadhyay, Pralay; Hungria, Vania; Dimopoulos, Meletios Athanasios